Unicycive Therapeutics Inc
General ticker "UNCY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $61.6M
Unicycive Therapeutics Inc does not follow the US Stock Market performance with the rate: -25.1%.
Estimated limits based on current volatility of 4.6%: low 0.64$, high 0.70$
Factors to consider:
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.36$, 1.25$]
- 2024-12-30 to 2025-12-30 estimated range: [0.40$, 1.34$]
Financial Metrics affecting the UNCY estimates:
- Negative: Non-GAAP EPS, $ of -0.87 <= 0.10
- Negative: Operating profit margin, % of -96.85 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -56.89 <= 2.35
Short-term UNCY quotes
Long-term UNCY plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.95MM | $0.68MM |
| Operating Expenses | $8.98MM | $19.00MM | $21.45MM |
| Operating Income | $-8.98MM | $-18.05MM | $-20.77MM |
| Non-Operating Income | $-1.04MM | $-0.01MM | $-9.77MM |
| Interest Expense | $0.63MM | $0.01MM | $0.08MM |
| R&D Expense | $6.08MM | $12.44MM | $12.90MM |
| Income(Loss) | $-10.02MM | $-18.06MM | $-30.54MM |
| Profit(Loss) | $-10.02MM | $-18.06MM | $-30.54MM |
| Stockholders Equity | $16.48MM | $-0.47MM | $-3.81MM |
| Assets | $18.74MM | $2.82MM | $14.19MM |
| Operating Cash Flow | $-5.77MM | $-15.65MM | $-18.28MM |
| Capital expenditure | $0.03MM | $0.00MM | $0.01MM |
| Investing Cash Flow | $-0.03MM | $-0.00MM | $-0.01MM |
| Financing Cash Flow | $22.38MM | $-0.47MM | $27.54MM |
| Earnings Per Share* | $-0.71 | $-1.20 | $-1.28 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.